BioDevelops Pharma GmbH Company Profile

03:13 EST 14th November 2019 | BioPortfolio

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operations a few months later at the Institute for Pharmacology in Vienna and focused on strategies for treatment of cystic fibrosis. In Sept. 2004, the Medical University of Vienna sold respective IP rights to BioDevelops. Consequently, the company filed a US-patent for an approach to enhance cell surface expression of proteins targeting Protein-Folding Diseases. The preliminary data - obtained with the A2A-receptor - were later supported with experimental findings on CFTR, the protein which is mutated in cystic fibrosis. The underlying research has been published recently (for full paper see T. Milojevic; for review see M. Toews). In addition to the IP transfer, the University granted to BioDevelops a right of first refusal for all IP related to the content of the original patent. Accordingly, BioDevelops also exerted its prerogative in sponsoring the July 2005 submission of a “second medical use” patent for proteasome inhibitors in the treatment of cystic fibrosis.


c/o Institute for PharmacologyWaehringer Strasse 13A


Phone: 43.1.710.6616
Fax: 43.1.710.6614

News Articles [1211 Associated News Articles listed on BioPortfolio]

EVER Pharma übernimmt Amneal Deutschland GmbH und erweitert Vertriebspräsenz in Europa

EVER Pharma Holding Ges.m.b.H. (Österreich) verkündete heute die Übernahme der Amneal Deutschland GmbH bekannt, einer Tochtergesellschaft von Amneal Pharmaceuticals, die das kommerzielle Geschäft ...

Heidelberg Pharma: Produktionsoptimierung verzögern Klinikstart für HDP-101

Frankfurt am Main ( - Heidelberg Pharma-Aktienanalyse von Analyst Thomas J. Schießle von der EQUI.TS GmbH: Thomas J. Schießle, Analyst der EQUI.TS GmbH, rät in einer aktuellen Ak...

EVER Pharma acquires Amneal Deutschland GmbH and extends its commercial presence in Europe

EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals that operates the ...

Heidelberg Pharma erhält Forschungsgelder

Die Heidelberg Pharma AG (ISIN: DE000A11QVV0) gab heute bekannt, dass ihre Tochtergesellschaft Heidelberg Pharma Research GmbH Forschungsgelder von der Europäischen Union erhalten wird. Heidelberg .....

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics schließt Übernahme von Vektor Pharma TF GmbH ab

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics schließt Übernahme von Vektor Pharma TF GmbH ab Vancouver, Kanada (17. September 2019). XPhyto Therapeutics Corp. (CSE:XPHY; FWB:4XT) (XPh.....

Pediapharm acquires rheumatology-focused Medac

Pediapharm Inc. acquired privately-held specialty pharmaceuticals company Medac Pharma Inc. (wholly owned subsidiary of German pharma medac GMBH) for total consideration of $50mm.

ACG acquires pharma processing equipment provider Xertecs GmbH

The goal is to give customers the best of both continents: sophisticated European design combined with Indian value-centric engineering and manufacturing

B.R.A.I.N.: Vorschuss-Lorbeeren?

Frankfurt am Main ( - B.R.A.I.N.-Aktienanalyse von der EQUI.TS GmbH: Thomas J. Schießle und Daniel Großjohann, Aktienanalysten der EQUI.TS GmbH, nehmen in einer aktuellen Aktiena....

Drugs and Medications [69 Associated Drugs and Medications listed on BioPortfolio]

La prairie switzerland [juvena produits de beaute gmbh]

Package.Label Principle Display Panel

Tobramycin [holopack verpackungstechnik gmbh]

Tobramycin Inhalation Solution (300 mg/5 mL)

Lonhala [holopack verpackungstechnik gmbh]

Glycopyrrolate Inhalation Solution (25 µg/mL)

Etoposide [thymoorgan gmbh pharmazir & co. k.g]

Etoposide Injection, USP

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

PubMed Articles [36 Associated PubMed Articles listed on BioPortfolio]

Data science tools and applications on the way to Pharma 4.0.

Multiple obstacles are driving the digital transformation of the biopharmaceutical industry. Novel digital techniques, often marketed as 'Pharma 4.0', are thought to solve some long-existing obstacles...


Participants of Pharma-sponsored research are exposed to risks, benefits, and uncertainties that do not occur in other forms of clinical studies. Ethics committees represent the subjects' first line o...

The Art of Virtualizing Pharma R&D.

Physicians in the pharmaceutical industry: their roles, motivations, and perspectives.

Although physicians occupy a significant number of key positions in the pharmaceutical industry, practicing clinicians are often unaware of the variety of career paths within this industry, or of the ...

Potential effects of increased openness in pharma: the original knowledge behind new drugs.

This study seeks to determine potential changes in the degree of openness in pharmaceutical R&D by investigating where the knowledge behind new molecular entities (NMEs) comes from in terms of type of...

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects

The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics

A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects

The purpose of this trial is to compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co., Ltd and ISMO Retar...

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of orally ...

Companies [1341 Associated Companies listed on BioPortfolio]

BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phas...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...


INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the m...


CROMA-PHARMA is a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology...


On June 29, 2000, ratiopharm GmbH, Europe's largest generic drug company, purchased Technilab Pharma to establish ratiopharm's generic operations in Canada. Long before being acquired by ratiopharm Gm...

More Information about "BioDevelops Pharma GmbH" on BioPortfolio

We have published hundreds of BioDevelops Pharma GmbH news stories on BioPortfolio along with dozens of BioDevelops Pharma GmbH Clinical Trials and PubMed Articles about BioDevelops Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioDevelops Pharma GmbH Companies in our database. You can also find out about relevant BioDevelops Pharma GmbH Drugs and Medications on this site too.

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Corporate Database Quicklinks

Searches Linking to this Company Record